Finance

Lists
Why is CTNM down 3,25%?
Dive Deeper
CTNM:NASDAQ
Contineum Therapeutics Inc
9,24 US$
-3,25%
(-0,31) 1D
9,24 US$
0,00% (0,00)
After hours
Closed: 18 ნოე, 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
9,57 US$
High
9,85 US$
Low
9,23 US$
Mkt. cap
362,82 მლნ.
Avg. vol.
1,01 მლნ.
Volume
0,00
52-wk high
17,78 US$
52-wk low
6,72 US$
EPS
-1,77 US$
Shares outstanding
35,35 მლნ.
No. of employees
51
Open
9,57 US$
High
9,85 US$
Low
9,23 US$
Mkt. cap
362,82 მლნ.
Avg. vol.
1,01 მლნ.
Volume
0,00
52-wk high
17,78 US$
52-wk low
6,72 US$
EPS
-1,77 US$
Shares outstanding
35,35 მლნ.
No. of employees
51
News stories
From web sources and news partners
About Contineum Therapeutics Inc
CEO-
Employees51
Founded2009
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current 9,24 US$
30,00 US$ (+224,68%)
Average
22,14 US$ (+139,61%)
Lowest
14,00 US$ (+51,52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Hold
Reiterated
17,00 US$
+84%
11/18/2026
Brian Abrahams
RBC Capital
Buy
Maintained
21,00 US$
+127,3%
11/03/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
30,00 US$
+224,7%
11/03/2026
Charles Moore
Robert W. Baird
Hold
Downgraded
14,00 US$
+51,5%
10/14/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
28,00 US$
+203%
10/12/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/30/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
23,00 US$
+148,9%
09/29/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
22,00 US$
+138,1%
09/16/2026
Last report
3 ნოე. 2026
Fiscal period
Q3 2026
-0,49 US$ / -0,45 US$
-8,20%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12,00 მლნ.
11,14 მლნ.
11,97 მლნ.
15,26 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,12 მლნ.
5,76 მლნ.
5,45 მლნ.
5,70 მლნ.
Operating expense
17,12 მლნ.
16,90 მლნ.
17,43 მლნ.
20,97 მლნ.
Total operating expenses
17,12 მლნ.
16,90 მლნ.
17,43 მლნ.
20,97 მლნ.
Operating income
-17,12 მლნ.
-16,90 მლნ.
-17,43 მლნ.
-20,97 მლნ.
Other non operating income
-51,00 ათ.
-57,00 ათ.
-68,00 ათ.
-93,00 ათ.
EBT including unusual items
-15,16 მლნ.
-14,46 მლნ.
-15,15 მლნ.
-18,70 მლნ.
EBT excluding unusual items
-15,16 მლნ.
-14,46 მლნ.
-15,15 მლნ.
-18,70 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15,16 მლნ.
-14,46 მლნ.
-15,15 მლნ.
-18,70 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,49
-0,39
-0,40
-0,49
Interest and investment income
2,01 მლნ.
2,50 მლნ.
2,34 მლნ.
2,36 მლნ.
Interest expense
-
-
-
-
Net interest expenses
2,01 მლნ.
2,50 მლნ.
2,34 მლნ.
2,36 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-17,03 მლნ.
-16,82 მლნ.
-17,29 მლნ.
-20,88 მლნ.
Gain or loss from assets sale
-
2,00 ათ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები